M
Michele DeRobertis
Researcher at Cedars-Sinai Medical Center
Publications - 44
Citations - 2509
Michele DeRobertis is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Mitral valve & Mitral valve replacement. The author has an hindex of 27, co-authored 44 publications receiving 2463 citations. Previous affiliations of Michele DeRobertis include University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Twenty-year comparison of tissue and mechanical valve replacement.
Steven S. Khan,Alfredo Trento,Michele DeRobertis,Robert M. Kass,Meenu Sandhu,Lawrence S.C. Czer,Carlos Blanche,Sharo Raissi,Gregory P. Fontana,Wen Cheng,Aurelio Chaux,Jack M. Matloff +11 more
TL;DR: Tissue and mechanical valve recipients have similar survival over 20 years of follow-up and the primary tradeoff is an increased risk of hemorrhage in patients receiving mechanical aortic valve replacements and an increasedrisk of late reoperation in all patients receiving tissue valve replacements.
Journal ArticleDOI
Discrepancies between Doppler and catheter gradients in aortic prosthetic valves in vitro. A manifestation of localized gradients and pressure recovery.
TL;DR: To evaluate possible causes of discrepancy between Doppler and catheter gradients across prosthetic valves, five sizes (19-27 mm) of St. Jude and Hancock valves were studied in an aortic pulsatile flow model.
Discrepancies Between Doppler andCatheter Gradients inAortic Prosthetic Valves InVitro AManifestation ofLocalized Gradients andPressure Recovery
TL;DR: In this article, the authors evaluate possible causes of discrepancy between Doppler and catheter gradients across prosthetic valves, five sizes (19-27 mm) of St. Jude and Hancockvalves were studied in anaortic pulsatile flow model.
Journal ArticleDOI
The St. Jude valve. Thrombolysis as the first line of therapy for cardiac valve thrombosis.
TL;DR: Thrombolytic therapy can be used as the first line of therapy for thrombosed St. Jude valves with a low risk of permanent side effects and excellent chances of success.
Journal ArticleDOI
In the current era, complete revascularization improves survival after coronary artery bypass surgery.
Thomas Kleisli,Wen Cheng,Milagros J. Jacobs,James Mirocha,Michele DeRobertis,Robert M. Kass,Carlos Blanche,Gregory P. Fontana,Sharo Raissi,Kathy E. Magliato,Alfredo Trento +10 more
TL;DR: Complete revascularization and arterial grafting improve 5-year survival and off-pump techniques do not affect survival.